Has Timothy Trainor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,795 in general payments to Timothy Trainor, MD across 711 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Timothy Trainor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Timothy Trainor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Timothy Trainor, MD

Gastroenterology · Slidell, LANPI 1871555136

Payments from drug & device makers

$10,795in general payments, 2019–2025

Across 711 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$3K
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
Takeda Pharmaceuticals U.S.A., Inc.$899
Johnson & Johnson$883
Pfizer$576
Gilead$556
plus $3K from 28 others

What the payments were for

Food & beverage$10,55598%
Education$2402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	217	$3,362
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	122	$1,475
Takeda Pharmaceuticals U.S.A., Inc.	72	$899
Johnson & Johnson	60	$883
Pfizer	41	$576
Gilead	26	$556
Bristol Myers Squibb	31	$391
Merck	22	$353
Ironwood Pharmaceuticals, Inc	25	$299
Intercept Pharmaceuticals, Inc.	17	$244
Boston Scientific	2	$225
Lilly USA, LLC	6	$174
Nestle Healthcare Nutrition Inc.	5	$145
Conmed Corporation	1	$132
Regeneron Healthcare Solutions, Inc.	1	$126
QOL Medical, LLC	8	$122
Ardelyx, Inc.	5	$111
Romark Laboratories, LC	8	$103
Daiichi Sankyo Inc.	6	$96
Sanofi	4	$87
Shionogi Inc	4	$68
UCB, Inc.	4	$59
Alfasigma USA, Inc.	3	$49
Shire North American Group Inc	3	$40
Redhill Biopharma Inc.	3	$37
Pharmacosmos Therapeutics Inc.	2	$37
Axonics, Inc.	2	$35
Ferring Pharmaceuticals Inc.	2	$23
Braintree Laboratories, Inc.	1	$21
Amgen	1	$20
Celltrion USA Inc.	1	$19
Evoke Pharma, Inc.	1	$15
Phathom Pharmaceuticals, Inc.	1	$14
Gastrogpo, LLC	4	$0

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,795 in reported general payments places this provider in the 70th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$37,427

Medicare patients

191

Services billed

311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CreonLipase/Protease/Amylase	16	$68,011
IbsrelaTenapanor Hcl	13	$22,001
LinzessLinaclotide	16	$21,950
Pantoprazole Sodium	373	$4,501
Sucralfate	22	$3,020
Dicyclomine Hcl	113	$2,540
Budesonide DrBudesonide	14	$1,532
Colestipol Hcl	14	$1,299
Esomeprazole Magnesium	26	$847
Omeprazole	86	$727
Rabeprazole Sodium	16	$599
Famotidine	87	$495
Ursodiol	11	$478
Azathioprine	16	$393
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	19	$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieCreon, Linzess	$3,362	$89,96132 claims
Ardelyx, Inc.Ibsrela	$111	$22,00113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 254 gastroenterology providers in Louisiana.